Prospective study for evaluating feasibily and utility of comprehensive genomic profiling test before initial systemic treatment in advanced malignant solid tumor patients

Prospective study for evaluating feasibily and utility of comprehensive genomic profiling test before initial systemic treatment in advanced malignant solid tumor patients - Upfront NCC Oncopanel Advanced medical Care

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040743

Enrollment

200

Registered

2020-06-12

Start date

2020-06-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or recurrent solid cancer (non-small cell lung cancer, breast cancer, gastric cancer, colorectal cancer, pancreatic cancer, or biliary tract cancer)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age over 16 years 2. Diagnosed with non-small cell lung cancer (EGFR/ALK/ROS-1/BRAF: negative), breast cancer (triple negative), gastric cancer, colon cancer, pancreatic cancer, and bile duct cancer. 3. Advanced disease (metastatic and/or refractory) 4. Treatment naive 5. ECOG PS 0 to 1 6. Adequate organ function 7. Tissue samples for NCC Oncopanel test 8. Registration of C-CAT 9. Written informed consent

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Rate of patients treated with matched targeted therapy based on the results of NCC oncopnel test (actionable gene alterations).	—

Countries

Japan

Contacts

Public ContactSachie Kawabata

National Cancer Center Hospital Project Management Section

NCCH1908_office@ml.res.ncc.go.jp03-3542-2511

Outcome results